48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Total Knee Arthroplasty
Conditions
Total Knee Arthroplasty
Trial Timeline
Nov 1, 2007 → Feb 1, 2012
NCT ID
NCT01111513About 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics
48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics is a pre-clinical stage product being developed by Sanofi for Total Knee Arthroplasty. The current trial status is completed. This product is registered under clinical trial identifier NCT01111513. Target conditions include Total Knee Arthroplasty.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01111513 | Pre-clinical | Completed |
Competing Products
11 competing products in Total Knee Arthroplasty
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirin | Daiichi Sankyo | Approved | 85 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |
| Glucagon receptor antagonist LY2409021 + Placebo | Eli Lilly | Pre-clinical | 23 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| LNA043 + Placebo | Novartis | Phase 1 | 33 |
| Denosumab | Amgen | Phase 2 | 51 |
| Exacyl® | Bayer | Phase 3 | 74 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| etoricoxib (MK0663) 120 mg + Comparator: Placebo + etoricoxib (MK0663) 90 mg | Organon | Phase 3 | 72 |
| Ceftobiprole | Basilea Pharmaceutica | Phase 1 | 28 |